Drug Trial Radar · NCT04541589
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
Last checked: Nov 19, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
206
Actual
Start
Jan 5, 2021
Primary completion
Aug 19, 2024
Study completion Aug 19, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and tolerability of iscalimab at two dose levels in patients with Sjögren's Syndrome, who participated in the TWINSS core study, CCFZ533B2201 (NCT03905525). Additionally, this Extension study will further explore the pharmacokinetics (PK) and efficacy of iscalimab at two dose level.
Conditions
- Sjogren's Syndrome
Interventions
IscalimabDrug
Iscalimab 600 mg or 300 mg was administered subcutaneously weekly for the first 3 weeks. Subsequently, iscalimab was administered subcutaneously bi-weekly (every other week or Q2W).
PlaceboOther
Placebo (1 injection of 2 ml) administered to participants in the iscalimab 300 mg arm to maintain blinding until the final database lock of the core study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From start of extension study up to 14 weeks after last study-drug administration or end of study (whichever occurred earlier), assessed up to approximately 60 weeks
Locations
62 sites in 23 countries. Site status is shown where the registry gives one.
North GA Rheumatology Group PC
Suwanee, Georgia
Ochsner Health System
Baton Rouge, Louisiana
The John Hopkins Jerome L Greene Sjogren
Baltimore, Maryland
Tufts School of Dental Medicine
Boston, Massachusetts
Winthrop University Hospital
Mineola, New York
Perelman School of Medicine
Philadelphia, Pennsylvania
Uni Wisconsin School Med Pub Health
Madison, Wisconsin
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
Ciudad Autonoma de Bs As, Buenos Aires, Argentina
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Vitória, Espírito Santo, Brazil
Novartis Investigative Site
Juiz de Fora, Minas Gerais, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Rimouski, Quebec, Canada
Novartis Investigative Site
Trois-Rivières, Quebec, Canada
Novartis Investigative Site
Santiago, Chile
Novartis Investigative Site
Santiago, Chile
Novartis Investigative Site
Valdivia, Los Ríos Region, Chile
Novartis Investigative Site
Santiago, RM, Chile
Novartis Investigative Site
Medellín, Antioquia, Colombia
Novartis Investigative Site
Barranquilla, Atlántico, Colombia
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Le Kremlin-Bicêtre, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Freiburg im Breisgau, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Szeged, Hungary
Novartis Investigative Site
Székesfehérvár, Fejér, Hungary
Novartis Investigative Site
Haifa, Israel
Novartis Investigative Site
Kfar Saba, Israel
Novartis Investigative Site
Ramat Gan, Israel
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Pisa, PI, Italy
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.